Lake Street Capital Trims BIOFRONTERA AG/ADR (NASDAQ:BFRA) Target Price to $21.00

BIOFRONTERA AG/ADR (NASDAQ:BFRA) had its target price cut by Lake Street Capital from $24.00 to $21.00 in a report published on Wednesday morning, The Fly reports. They currently have a buy rating on the stock.

Separately, Benchmark restated a buy rating on shares of BIOFRONTERA AG/ADR in a research report on Tuesday, March 26th.

NASDAQ:BFRA opened at $16.47 on Wednesday. BIOFRONTERA AG/ADR has a 12 month low of $11.04 and a 12 month high of $18.32. The company has a current ratio of 3.84, a quick ratio of 3.38 and a debt-to-equity ratio of 1.56. The company has a 50-day moving average price of $16.73.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings results on Wednesday, May 29th. The company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. The firm had revenue of $7.73 million for the quarter. BIOFRONTERA AG/ADR had a negative net margin of 62.81% and a negative return on equity of 95.81%.

About BIOFRONTERA AG/ADR

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

See Also: Bond

The Fly

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.